Review
Copyright ©The Author(s) 2021.
World J Clin Cases. Jul 26, 2021; 9(21): 5754-5768
Published online Jul 26, 2021. doi: 10.12998/wjcc.v9.i21.5754
Table 1 Data from phase III trials for first-line and second-line therapy of hepatocellular carcinoma

Drugs
Level of evidence
Absolute OS (mo)
Comparison between OS
ORR
ClinicalTrials.gov Number
First-line setting
SHARP[7] (n = 602)Sorafenib vs placeboPhase III10.7 vs 7.9HR 0.69 (95%CI: 0.55-0.78)RECIST, 2% vs 1%NCT00105443
Asia-Pacific[8] (n = 271)Sorafenib vs placeboPhase III6.5 vs 4.2HR 0.68 (95%CI: 0.50-0.93)RECIST, 3.3% vs 1.3%NCT00492752
REFLECT[9] (n = 954)Lenvatinib vs SorafenibPhase III13.6 vs 12.3HR 0.92 (95%CI: 0.79-1.06)mRECIST, 24.1% vs 9.2%NCT01761266
IMbrave150[36] (n = 501)Atezolizumab + Bevacizumab vs SorafenibPhase IIINE vs 13.2HR 0.58 (95%CI: 0.42-0.79)RECIST 1.1, 27% vs 12%; mRECIST, 33.2% vs 13.3%NCT03434379
Second-line setting
RESORCE[10] (n = 573)Regorafenib vs placeboPhase III10.6 vs 7.8HR 0.63 (95%CI: 0.50-0.79)mRECIST, 10.6% vs 4.1%NCT01774344
CESETIAL[11] (n = 707)Cabozantinib vs placeboPhase III10.2 vs 8.0HR 0.76 (95%CI: 0.63-0.92)RECIST 1.1, 4% vs 0.4%NCT01908426
REACH-2[13] (n = 292)Ramucirumab vs placeboPhase III8.5 vs 7.3HR 0.71 (95%CI: 0.53-0.95)RECIST 1.1, 4.6% vs 1.1%NCT02435433
CheckMate 459[39] (n = 743)Nivolumab vs SorafenibPhase III16.4 vs 14.7HR 0.85 (95%CI: 0.72-1.02)RECIST, 15% vs 7%NCT02576509
KEYNOTE-240[41] (n = 413)Pembrolizumab vs placeboPhase III13.9 vs 13.6 vs 10.9 HR 0.78, 95% CI: 0.61-0.99)RECIST 1.1, 18.3% vs 4.4%NCT02702401